AUG 20, 2026 · PHASE 3 TRIAL
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
ClinicalTrials.gov
This is a Phase 3 trial registration with no reported results; the study is actively recruiting and outcome data are not yet available.
Reported
Primary endpointProgression Free Survival (PFS) from random…
Planned follow-up durationUp to 33 months
Planned enrollment625